Guoping Jiang

79 Qingchun Rd
Hangzhou, 310003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma.

Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma.

Journal: International journal of biological sciences

Published: December 01, 2022

Primary Hepatoid Adenocarcinoma of the Lung: A Systematic Literature Review.

Primary Hepatoid Adenocarcinoma of the Lung: A Systematic Literature Review.

Journal: OncoTargets and therapy

Published: March 01, 2022

Characteristics of genomic alterations in Chinese cholangiocarcinoma patients.

Characteristics of genomic alterations in Chinese cholangiocarcinoma patients.

Journal: Japanese journal of clinical oncology

Published: November 21, 2019

Sonographic diagnosis of splenogonadal fusion in a 2-year-old boy.

Sonographic diagnosis of splenogonadal fusion in a 2-year-old boy.

Journal: Journal of clinical ultrasound : JCU

Published: June 15, 2016

Research on pediatric glomerular disease and normal kidney with shear wave based elastography point quantification.

Research on pediatric glomerular disease and normal kidney with shear wave based elastography point quantification.

Journal: Japanese journal of radiology

Published: April 07, 2016

CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation.

CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation.

Journal: Scientific reports

Published: December 16, 2015

An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.

An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.

Journal: Oncotarget

Published: April 04, 2015

Orosomucoid 2 inhibits tumor metastasis and is upregulated by CCAAT/enhancer binding protein β in hepatocellular carcinomas.

Orosomucoid 2 inhibits tumor metastasis and is upregulated by CCAAT/enhancer binding protein β in hepatocellular carcinomas.

Journal: Oncotarget

Published: February 10, 2015

Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies.

Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies.

Journal: BMC cancer

Published: August 12, 2014

Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma.

Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: August 20, 2013

Pulmonary lymphangitic carcinomatosis in liver carcinoma: a rare case report and literature review.

Pulmonary lymphangitic carcinomatosis in liver carcinoma: a rare case report and literature review.

Journal: World journal of surgical oncology

Published: July 01, 2013

G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma.

G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma.

Journal: PloS one

Published: December 19, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026